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ABSTRACT The abnormal proliferation of cancer cells is driven by deregulated on-
cogenes or tumor suppressors, among which the cancer-vulnerable genes are attrac-
tive therapeutic targets. Targeting mislocalization of oncogenes and tumor suppres-
sors resulting from aberrant nuclear export is effective for inhibiting growth
transformation of cancer cells. We performed a clustered regularly interspaced short
palindromic repeat (CRISPR)-associated (Cas) screening in a unique model of
matched primary and oncogenic Kaposi’s sarcoma-associated herpesvirus (KSHV)-
transformed cells and identiﬁed genes that were growth promoting and growth sup-
pressive for both types of cells, among which exportin XPO1 was demonstrated to
be critical for the survival of transformed cells. Using XPO1 inhibitor KPT-8602 and
by small interfering RNA (siRNA) knockdown, we conﬁrmed the essential role of
XPO1 in cell proliferation and growth transformation of KSHV-transformed cells and
in cell lines of other cancers, including gastric cancer and liver cancer. XPO1 inhibi-
tion induced cell cycle arrest through p53 activation, but the mechanisms of p53 ac-
tivation differed among the different types of cancer cells. p53 activation depended
on the formation of promyelocytic leukemia (PML) nuclear bodies in gastric cancer
and liver cancer cells. Mechanistically, XPO1 inhibition induced relocalization of au-
tophagy adaptor protein p62 (SQSTM1), recruiting p53 for activation in PML nuclear
bodies. Taken the data together, we have identiﬁed novel growth-promoting and
growth-suppressive genes of primary and cancer cells and have demonstrated that
XPO1 is a vulnerable target of cancer cells. XPO1 inhibition induces cell arrest
through a novel PML- and p62-dependent mechanism of p53 activation in some
types of cancer cells.
IMPORTANCE Using a model of oncogenic virus KSHV-driven cellular transformation
of primary cells, we have performed a genome-wide CRISPR-Cas9 screening to iden-
tify vulnerable genes of cancer cells. This screening is unique in that this virus-
induced oncogenesis model does not depend on any cellular genetic alterations and
has matched primary and KSHV-transformed cells, which are not available for similar
screenings in other types of cancer. We have identiﬁed genes that are both growth
promoting and growth suppressive in primary and transformed cells, some of which
could represent novel proto-oncogenes and tumor suppressors. In particular, we
have demonstrated that the exportin XPO1 is a critical factor for the survival of
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transformed cells. Using a XPO1 inhibitor (KPT-8602) and siRNA-mediated knock-
down, we have conﬁrmed the essential role of XPO1 in cell proliferation and in
growth transformation of KSHV-transformed cells, as well as of gastric and liver can-
cer cells. XPO1 inhibition induces cell cycle arrest by activating p53, but the mecha-
nisms of p53 activation differed among different types of cancer cells. p53 activation
is dependent on the formation of PML nuclear bodies in gastric and liver cancer
cells. Mechanistically, XPO1 inhibition induces relocalization of autophagy adaptor
protein p62 (SQSTM1), recruiting p53 for activation in PML nuclear bodies. These re-
sults illustrate that XPO1 is a vulnerable target of cancer cells and reveal a novel
mechanism for blocking cancer cell proliferation by XPO1 inhibition as well as a
novel PML- and p62-mediated mechanism of p53 activation in some types of cancer
cells.
KEYWORDS CRISPR-Cas9 screening, gastric cancer, human herpesvirus 8, HHV8,
Kaposi’s sarcoma, Kaposi’s sarcoma-associated herpesvirus, KSHV, liver cancer, PML
bodies, SQSTM1, p62, XPO1, p53
The malfunction of nuclear transport, which shuttles proteins between cytoplasmand nucleus, often leads to mislocalization of oncogenes and tumor suppressor
proteins in cancer cells (1). Indeed, numerous proteins involved in cancer, including
p53, adenomatous polyposis coli (APC), retinoblastoma (Rb), NFAT (nuclear factor of
activated T cells), and -catenin, are abnormally localized in cancer cells. The conse-
quence of these dysfunctions is either overactivation of oncogenes or inactivation of
tumor suppressor proteins, resulting in uncontrolled cell proliferation and growth
transformation (2).
Unlike passive diffusion of metabolites, shuttling of proteins between nucleus and
cytoplasm is an active, highly regulated receptor-mediated process. The nuclear pore
complex (NPC) is a supramolecular structure composed of more than 30 nucleoporins
interacting with importins and exportins within the NPC channel. The directionality of
the transport depends on the distribution of GTP- or GDP-bound GTPase, the Ran
protein, in both cytoplasmic and nucleic compartments (3). Indeed, while importins
bind to their cargo proteins in cytoplasm and release them in nucleus upon binding of
RanGTP, exportins bind to cargos in nucleus only in the presence of RanGTP and release
them in cytoplasm upon Ran-driven GTP hydrolysis (4).
The exportin family consists of 7 members, including XPO1 (CRM1), XPO2 (CSE1L),
XPO3 (XPOt), XPO4, XPO5, XPO6, and XPO7. While XPO1, XPO2, XPO4, XPO6, and XPO7
primarily mediate the export of cargo proteins, XPO3 and XPO5 are involved in the
transport of tRNAs and precursor microRNAs (pre-miRNAs), respectively. XPO1, the
major protein export receptor, is also associated with the nuclear export of mRNAs and
rRNAs (5).
Mechanistically, XPO1 interacts with the nucleoporins NUP214 and NUP88 inside the
NPC and exports proteins containing XPO1-speciﬁc nuclear export signal (NES) se-
quences, which are short leucine-rich sequences. Several tumor suppressor proteins
and oncogenes display XPO1-speciﬁc NES (6). Consequently, XPO1 dysregulation indi-
rectly regulates cellular functions such as cell proliferation and cellular transformation,
apoptosis, and chromosome segregation (2). In particular, XPO1 is upregulated in
ovarian carcinoma, glioma, osteosarcoma, and pancreatic, cervical, and gastric cancers,
resulting in induction of abnormal accumulation of the tumor suppressor proteins Rb,
APC, p53, p21, and p27 in the cytoplasm, leading to losses of their nuclear functions (2).
On the other hand, inhibition of XPO1 by RNA interference or with inhibitors, such as
leptomycin B or selective inhibitors of nuclear export (SINE), prevents cellular transfor-
mation and tumorigenesis in numerous cancer models. Hence, XPO1 has become a
promising target in cancer therapy (7).
Nuclear bodies (NBs) are membraneless structures within the nucleus involved in
multiple pathways of genome maintenance. Among them, promyelocytic leukemia
protein nuclear bodies (PML-NBs) are involved in DNA repair, DNA damage response,
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telomere homeostasis, and p53-associated apoptosis and cell cycle arrest (8). Among
the various biological consequences of XPO1 inhibition, several groups observed the
retention of p53, the most extensively described tumor suppressor, in the nucleus,
enhancing p53-mediated tumor suppressor activity (8). Indeed, activation of p53
induces cell cycle arrest and apoptosis in many types of cancer cells. In particular,
inside the nucleus, p53 colocalizes and interacts with PML-NBs, which serve as p53
coactivators (9). PML knockout impairs p53-dependent apoptosis and p53-mediated
transcriptional activation, as well as induction of p53 target genes such as Bax and p21
(9). Therefore, PML-NBs may play a signiﬁcant role in apoptosis and cancer. Neverthe-
less, the underlying molecular mechanism mediating PML-dependent p53 activation is
still unclear.
The development of new genome engineering technologies has enabled the iden-
tiﬁcation of oncogenes and tumor suppressors in cancer cells in vitro and in vivo (10,
11). In particular, the clustered regularly interspaced short palindromic repeat (CRISPR)-
associated (Cas) protein system, adapted to mammalian cells on the basis of a mech-
anism of adaptive immunity of bacteria and archaea, enhances the accessibility of
genome manipulation by allowing the targeting of genes with speciﬁc RNA sequences
(12). Brieﬂy, CRISPR relies on Cas9 guided by single guide RNAs (sgRNAs; CRISPR RNAs)
to induce loss-of-function (LOF) mutations via frameshifts in the coding region, leading
to gene inactivation. The CRISPR-Cas9 system has enabled different types of genetic
modiﬁcations, such as gene disruption and transcriptional activation. Several types of
biological screens based on the CRISPR-Cas9 system have already been carried out to
identify viral restriction factors, oncogenes, and tumor suppressors, as well as to
develop T-cell immunotherapies.
In this study, by performing a genome-wide CRISPR-Cas9 screening of cells trans-
formed by an oncogenic virus, namely, Kaposi’s sarcoma-associated herpesvirus (KSHV),
we have identiﬁed cellular genes that are essential for cellular transformation (13).
Brieﬂy, CRISPR pooled libraries containing sgRNAs that speciﬁcally target all known
cellular genes were transduced into Cas9-expressing KSHV-transformed primary rat
mesenchymal embryonic stem (KMM) cells and control primary rat mesenchymal stem
(MM) cells (13). Genomic DNAs from surviving MM cells and KMM cells were collected
at days 1, 4, 11, and 21 postransduction and sequenced, and the results were analyzed
for the gain or loss of sgRNAs. We identiﬁed exportin family members XPO1, XPO2,
XPO3, XPO5, and XPO7 as the essential factors involved in the survival of KMM cells. We
conﬁrmed the essential role of XPO1 in cell proliferation and growth transformation
using cell lines of other types of cancer, including AGS cells derived from gastric cancer
and HUH7 cells derived from liver cancer. We showed that inhibition of XPO1 by small
interfering RNAs (siRNAs) or with a XPO1 inhibitor, KPT-8602, blocked cell proliferation
and growth transformation by inducing p53-mediated cell cycle arrest in all types of
cancer cells tested. However, we found that the mechanisms mediating p53 activation
differed among different types of cancer cells. In AGS and HUH7 cells, p53 activation
was correlated with nuclear accumulation of autophagy adaptor protein p62 (SQSTM1),
which was colocalized with p53 within the PML-NBs. Knockdown of p62 with siRNAs
abrogated p53 activation induced by XPO1 inhibition. These results highlight an
essential role of p62 in controlling cell proliferation and growth transformation by
mediating activation of the p53 pathway in some types of cancer cells.
RESULTS
Genome-wide CRISPR-Cas9 screening for essential genes of KSHV-transformed
cells. KSHV is an oncogenic virus which regulates numerous growth-promoting and
survival pathways (14). We have previously shown that infection by KSHV alone is
sufﬁcient to efﬁciently infect and transform MM cells without depending on cellular
genetic alterations and that KSHV-transformed KMM cells can efﬁciently induce tumors
in nude mice with pathological features resembling Kaposi’s sarcoma (KS) (13). Because
of the unique features of KSHV-induced cellular transformation and the available
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matched primary MM cells, KMM cells are ideal for identifying essential cellular genes
that mediate growth transformation.
We ﬁrst generated MM cells and KMM cells stably expressing Cas9 by lentiviral
transduction following by positive selection with blasticidin for 1 week. Interestingly,
we repeatedly observed weaker expression of Cas9 protein in MM cells than in KMM
cells in multiple experiments (see Fig. S1A in the supplemental material). This was likely
due to a higher rate of cell proliferation of KMM cells than of MM cells, often leading
to higher expression levels of genes (13, 15). Despite the differential levels of Cas9
expression, we observed efﬁcient inhibition of the endogenous SIRT1 expression after
lentiviral transduction of sgRNAs targeting SIRT1 in both Cas9-expressing MM cells and
KMM cells (Fig. S1B). Importantly, Cas9 expression did not affect the efﬁciency of colony
formation of KMM cells in soft agar (Fig. S1C). As expected, Cas9-expressing MM cells
did not form any colonies in soft agar (13). These results indicate that the Cas9-
expressing MM cells and KMM cells can be used for identifying essential cellular genes
that mediate growth transformation.
We then generated a library of sgRNAs targeting 19,840 genes of the rat genome,
each with 3 independent sgRNAs. Cas9-expressing MM cells and KMM cells were
transduced with the lentiviral sgRNA library and selected for 3 days with puromycin.
The cultures were then switched to normal medium without any selection, and cell
samples were collected at days 1, 4, 11, and 21 and subjected to DNA sequencing to
determine the gain and loss sgRNAs over time (Fig. 1A). Cumulative frequencies of
sgRNAs were analyzed at days 1, 4, 11, and 21 postransduction in MM cells and KMM
cells (Fig. 1B). Compared to day 1, we observed a progressive shift to the left in the
curves at days 4, 11, and 21 postransduction, indicating depletion of a subset of
sgRNAs. By assessing the global gene vulnerability levels at days 4, 11, and 21
postransduction, we observed a lower abundance of essential genes, displaying as
negative CRISPR scores, in KMM cells than in MM cells, suggesting that KMM cells had
higher survival rates than MM cells (Fig. 1B), which was also shown by the CRISPR scores
of individual genes (Fig. 1C). Interestingly, the correlation between CRISPR score and
gene expression at the RNA level (16) was observed neither in MM cells nor in KMM
cells (Fig. S2). Finally, gene set enrichment analysis (GSEA) data from day 21 versus day
1 postransduction revealed enrichments of gene signatures in housekeeping pathways,
including DNA replication, transcription, and translation, whose levels were signiﬁcantly
higher in KMM cells than in MM cells, conﬁrming that the MM cells were more
susceptible to gene disruption than the KMM cells (Fig. 1D).
Identiﬁcation of essential genes and pathways of KSHV-transformed cells by
CRISPR-Cas9 screening. Since essential genes are likely to encode key regulators of
cellular processes involved in the survival of cancer cells, several studies previously
investigated the overlapping of essential genes across different cancer cell lines by
CRISPR-Cas9 screening (17). Therefore, we correlated results from MM cells and KMM
cells with those of previous studies in chronic myeloid leukemia (CML) cell lines (KBM7
and K562) and Burkitt’s lymphoma cell lines (Raji and Jiyoye). We found a high degree
of overlap in gene essentiality between KSHV-transformed cells and other types of
cancer cells (R20.29) (Fig. 2A). On the other hand, the correlation of essential genes
between the primary MM cells and other types of cancer cells remained low (R2 
0.09).
We next classiﬁed the 19,840 genes based on CRISPR scores. For each type of cells,
we ﬁrst selected genes with CRISPR scores that were statistically different between day
21 and day 1 and then those with CRISPR scores that were statistically different
between KMM and MM cells and obtained 9 groups of genes (Fig. 2B; see also Table S1
in the supplemental material). Group 1 consisted of 11 genes that had a signiﬁcant
increase in CRISPR score for KMM cells but a signiﬁcant decrease in CRISPR score for MM
cells; group 2 consisted of 680 genes that had a signiﬁcant increase in CRISPR score for
KMM cells but no signiﬁcant change in CRISPR score for MM cells; group 3 consisted of
51 genes that had signiﬁcant increases in CRISPR score for both KMM and MM cells;
group 4 consisted of 402 genes that had no signiﬁcant change in CRISPR score for KMM
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FIG 1 Genome-wide CRISPR-Cas9 screening for essential genes of KSHV-transformed cells. (A) Experimental design of CRISPR-Cas9
high-throughput screening in KSHV-transformed cells (KMM) in and matched primary MM cells. (B) Analysis of the cumulative
(Continued on next page)
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cells but had a signiﬁcant decrease in CRISPR score for MM cells; group 5 consisted of
16,558 genes that had no signiﬁcant change in CRISPR score for both KMM and MM
cells; group 6 consisted of 552 genes that had no signiﬁcant change in CRISPR score for
KMM cells but had a signiﬁcant increase in CRISPR score for MM cells; group 7 consisted
of 314 genes that had signiﬁcant decreases in CRISPR score for both KMM and MM cells;
group 8 consisted of 1,259 genes that had a signiﬁcant decrease in CRISPR score for
KMM cells but had no signiﬁcant change in CRISPR score for MM cells; and group 9
consisted of 13 genes that had a signiﬁcant decrease in CRISPR score for KMM cells but
had a signiﬁcant increase in CRISPR score for MM cells.
Of these 9 groups, genes in group 8 were likely essential or pro-oncogenic for KMM
cells but not for MM cells; among them, 18 genes, including Naa38, Rpl9_like, Rpl23a,
Spcs3, Hspa14_like, Nfyb, Eif2b2, Mrpl55, Pold1, Nup43, Lin52, Csnk1a1, Aldoa, Rpl6,
Ddx6, Wdr74, Rars, and Cnot1, had CRISPR score ratios of 5 (32-fold) at day 21
compared to day 1 for KMM cells. Genes in group 2 were likely growth suppressive for
KMM cells but not MM cells. On the other hand, genes in group 4 were likely essential
or growth promoting for MM cells but not KMM cells whereas genes in group 6 were
likely growth suppressive for MM cells but not KMM cells, suggesting that KSHV might
target these two sets of genes to allow the transformed cells to overcome the essential
or growth-suppressive functions of these genes, respectively.
We determined the molecular pathways that were signiﬁcantly depleted and en-
riched in KMM cells compared to MM cells (day 21 versus day 1) by Ingenuity pathway
analysis (IPA) (see Table S2 and S3). We found that the eukaryotic initiation factor 2
(EIF2) pathway, the pathway controlling regulation of eIF4 and p70S6K, and the mTOR
pathway were the top 3 depleted pathways in KMM cells compared to MM cells,
highlighting their roles in the survival of the transformed cells (Fig. 2C). In fact, these
pathways are highly related to one another, and the mTOR pathway is the most
effective target for the treatment of KS (18), hence further validating the relevance of
this model for KS. On the other hand, we found that the hypoxia pathway and the p38
mitogen-activated protein kinase (MAPK) pathway were the pathways that were most
highly enriched in KMM cells compared to MM cells, suggesting their essential roles in
maintaining the homeostasis of the KSHV-transformed cells (Fig. 2D).
Identiﬁcation of XPO1 as a critical factor involved in cell proliferation and
growth transformation of cell lines derived from multiple types of cancer. Since
oncogenes and tumor suppressor proteins are often mislocalized as a result of dys-
regulation of nuclear transport (1), we focused on the exportin family members. The
counts of sgRNAs of XPO1, XPO2, XPO3, and XPO5 signiﬁcantly decreased at day 21
compared to day 1 in KMM cells, indicating the essential functions of these exportins,
whereas XPO7 sgRNA counts signiﬁcantly increased in KMM cells, indicating its putative
antisurvival effect in the transformed cells (Fig. S3). In addition, MM cells were sensitive
to XPO1, XPO2, and XPO5 knockout (Fig. S3). Numerous inhibitors have been devel-
oped for the main exportin member, XPO1. Some of these inhibitors are currently in
clinical trials for different types of cancer (19–21). Hence, we decided to focus on this
exportin.
Since XPO1 is upregulated in numerous types of cancer (22), we ﬁrst examined XPO1
expression in KMM cells compared to MM cells. We observed 3-fold-higher expression
level of XPO1 in KMM than in MM cells at the mRNA level (Fig. 3A), a ﬁnding that was
conﬁrmed at the protein level (Fig. 3B). Because KMM cells are latently infected by
KSHV, expressing viral latent genes LANA, vFLIP, vCyclin, and the miRNA cluster (13, 23),
we examined the roles of these genes in XPO1 expression. Deletion of either vCyclin or
the miRNA cluster but not vFLIP abolished XPO1 upregulation (Fig. 3A and B). Because
FIG 1 Legend (Continued)
frequency of sgRNAs at days 1, 4, 11, and 21 postransduction in MM cells and KMM cells. (C) Analysis of gene essentiality at days
4, 11, and 21 postransduction using CRISPR scores in MM cells and KMM cells. Genes are ranked by alphabetical order. (D) GSEA
of enriched pathways at day 21 versus day 1 postransduction in MM cells and KMM cells. PE Hi Sequencing, paired-end
high-throughput sequencing.
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FIG 2 Identiﬁcation of essential genes and pathways of KSHV-transformed cells. (A) Correlation of
essential genes among MM, KMM, Raji, Jiyoye, K562, and KBM7 cell lines (R2). (B) Classiﬁcation of the
19,840 genes into 9 different groups based on the ratio of the CRISPR score at day 21 to the score at day
1 and statistical signiﬁcance in results of comparisons MM versus KMM cells. Group 1 includes genes with
KMM Log2 CRISPR scores of 0 and P values of 0.05 and with MM Log2 CRISPR scores of 0 and P
values of 0.05; group 2 includes genes with KMM Log2 CRISPR scores of 0 and P values of 0.05 and
MM Log2 CRISPR scores with P values of 0.05; group 3 includes genes with both MM and KMM Log2
CRISPR scores of 0 and P values of 0.05; group 4 includes genes with KMM Log2 CRISPR scores with
P values of0.05 and MM Log2 CRISPR scores of0 and P values of0.05; group 5 includes genes with
both MM and KMM Log2 CRISPR scores with P values 0.05; group 6 includes genes with KMM Log2
(Continued on next page)
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LANA is essential for KSHV episome persistence, we were not able to obtain cells
latently infected by the LANA mutant (14). However, overexpression of LANA in MM
cells did not alter XPO1 expression (results not shown). By complementing cells
infected by the miRNA cluster deletion mutant (ΔmiR) with individual miRNAs, we
found that pre-miR-K3 mediated XPO1 upregulation (Fig. 3C). Hence, both vCyclin, a
homologue of cellular cyclin D2 (15), and pre-miR-K3, which activates the Akt pathway
(24), not only promote cell cycle progression and facilitate the G1/S-phase transition,
respectively (15, 23), but also cause XPO1 upregulation.
We performed RNA interference knockdown to conﬁrm the results obtained in
CRISPR-Cas9 screening in KMM cells as well as in cell lines of other types of cancer,
including AGS and HUH7 derived from gastric and liver cancers, respectively. The role
of XPO1 in gastric cancer has not been examined before and has been examined in liver
cancer only minimally (25). Knockdown of XPO1 decreased cell proliferation in KMM,
AGS, and HUH7 cells but had no effect on the primary MM cells (Fig. 3D to F). Using
XPO1-speciﬁc SINE compound KPT-8602, we observed signiﬁcant inhibition of cell
proliferation that occurred in a dose-dependent fashion starting at 0.1 M in KMM cells
and at 0.5 M in AGS and HUH7 cells (Fig. 3G). MM cells were sensitive to KPT-8602 only
at concentrations of 1 M. Furthermore, inhibition of XPO1 abrogated colony forma-
tion of KMM, AGS, and HUH7 cells in soft agar (Fig. 3H), indicating the essential role of
XPO1 in maintaining cellular transformation.
Inhibition of XPO1 induces p53 activation and cell cycle arrest. We examined
the molecular mechanism mediating the inhibition of cell proliferation by KPT-8602.
Treatment of MM, KMM, AGS, and HUH7 cells with KPT-8602 at 1 M for 24 h induced
cell cycle arrest at the G2/M phase in MM and KMM and at the G0/G1 phase in AGS and
HUH7 cells (Fig. 4A), suggesting different responses of these cells to KPT-8602. In
parallel, we observed an activation of the p53 pathway as shown by the increase of
phospho-p53 in KMM, AGS, and HUH7 cells but not MM cells after treatment with 1 M
KPT-8602 for 24 h (Fig. 4B). p53 activation has been shown to be dependent on
PML-NBs within the nucleus. Interestingly, both MM cells and KMM cells had strong
nuclear PML staining as well as cytoplasmic staining, with some cells showing staining
patterns similar to those seen with PML-NB, and KPT-8602 treatment did not alter the
PML staining pattern in those cells (Fig. 4C). These results indicated that PML-NBs were
unlikely to mediate p53 activation in KMM cells. In contrast, AGS cells had no nuclear
PML staining and only some HUH7 cells had weak nuclear PML staining, none of which
showed the staining pattern of PML-NBs (Fig. 4C). However, a pattern of strong nuclear
staining with PML-NBs was observed following KPT-8602 treatment in AGS and HUH7
cells (Fig. 4C). Signiﬁcantly, siRNA knockdown of PML (Fig. 4D), which disrupted
PML-NBs, inhibited KPT-8602-induced p53 phosphorylation in AGS and HUH7 cells,
highlighting the essential role of PML-NBs in p53 activation in these cells (Fig. 4E).
p53 activation in PML-NBs depends on the nuclear accumulation of autophagy
adaptor protein p62 (SQSTM1) in AGS and HUH7 cells. Since PML-NBs are thought
to form hybrid bodies with p62 protein during cellular stress (26), we investigated the
p62 protein after XPO1 inhibition in AGS and HUH7 cells. Treatment with 1 M
KPT-8602 for 24 h increased the expression level of p62 in AGS and HUH7 cells (Fig. 5A).
Interestingly, we observed nuclear translocation and accumulation of p62, which was
colocalized with p53 in AGS and HUH7 cells after KPT-8602 treatment (Fig. 5B).
Furthermore, p62 was colocalized with PML-NBs in AGS and HUH7 cells following XPO1
inhibition, which was consistent with the hypothesis of formation of hybrid bodies
FIG 2 Legend (Continued)
CRISPR scores with P values of 0.05 and MM Log2 CRISPR scores of 0 and P values of 0.05; group
7 includes genes with both MM and KMM Log2 CRISPR scores of 0 and P values of 0.05; group 8
includes genes with KMM Log2 CRISPR scores of 0 and P values of 0.05 and MM Log2 CRISPR scores
with P values of 0.05; group 9 includes genes with KMM Log2 CRISPR scores of 0 and P values of
0.05 and MM Log2 CRISPR scores of 0 and P values of 0.05. (C) IPA of top 10 depleted pathways
in KMM cells over MM cells at day 21 versus day 1 postransduction. (D) IPA of top 10 enriched pathways
in KMM cells over MM cells at day 21 versus day 1 postransduction.
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FIG 3 Identiﬁcation of XPO1 as a vulnerable gene of KSHV-transformed KMM cells and of cell lines of gastric cancer AGS and liver
cancer HUH7 cells. (A and B) XPO1 expression in MM cells and in MM cells infected by KSHV (KMM) and by mutant viruses with a
deletion of vFLIP (ΔvFLIP), vCyclin (ΔvCyclin), or a cluster of 10 pre-miRNAs (ΔmiR) analyzed by reverse transcription-quantitative PCR
(qRT-PCR) (A) and Western blotting (B). (C) Expression of XPO1 analyzed by qRT-PCR in MM cells, KMM cells, ΔmiR cells, or ΔmiR cells
complemented with individual KSHV pre-miRNAs (K1 to K12). (D) Expression of XPO1 following siRNA knockdown analyzed by Western
blotting in MM cells and KMM cells. (E) Expression of XPO1 following siRNA knockdown analyzed by Western blotting in AGS and HUH7
cells. (F) Analysis of cell proliferation following siRNA knockdown of XPO1 in MM, KMM, AGS, and HUH7 cell lines. (G) Analysis of cell
proliferation following treatment with DMSO or KPT-8602 at different concentrations for 3 days in MM, KMM, AGS, and HUH7 cells. (H)
Formation of colonies in soft agar following treatment with DMSO or KPT-8602 at 1 M in KMM, AGS, and HUH7 cells. Representative
ﬁelds are shown, and efﬁciencies of colony formation are presented.
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FIG 4 Inhibition of XPO1 induces PML-mediated p53 activation and cell cycle arrest. (A) Effect of KPT-8602 treatment on cell cycle progression
of MM, KMM, AGS, and HUH7 cells. Cells treated with 1 M KPT-8602 for 48 h were analyzed by ﬂow cytometry after BrdU and propidium iodide
staining. (B) Analysis of phospho-p53 (p-p53) and total p53 in MM, KMM, AGS, and HUH7 cells after treatment with 1 M KPT-8602 by Western
blotting. (C) Examination of PML in MM, KMM, AGS, and HUH7 cells after treatment with 1 M KPT-8602 for 24 h by immunoﬂuorescence assay.
The slides were counterstained with DAPI, and pictures were taken with a confocal microscopy (magniﬁcation, 600). (D) Expression of PML in
AGS and HUH7 cells following siRNA knockdown analyzed by Western blotting. (E) Analysis of p-p53 in AGS and HUH7 cells following siRNA
knockdown of PML analyzed by Western blotting.
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FIG 5 Induction of p62 nuclear accumulation and colocalization with p53 following XPO1 inhibition in
AGS and HUH7 cells. (A) Expression of p62 in MM, KMM, AGS, and HUH7 cells after treatment with 1 M
KPT-8602 for 24 h analyzed by Western blotting. (B) Expression of p53 and p62 in AGS, HUH7, MM, and
(Continued on next page)
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(Fig. 6A). The expression level of p62 was also increased in KMM cells but not in MM
cells (Fig. 5A). However, we did not observe nuclear translocation and accumulation of
p62 in MM cells and KMM cells, and there was no nuclear colocalization of p53 with p62
in these cells (Fig. 5B). Consistent with these results, there was no obvious nuclear
colocalization of p62 with PML-NBs in MM cells and KMM cells (Fig. 6A). These results
indicated that p62 was unlikely to be involved in p53 activation following XPO1
inhibition in KMM cells.
To investigate the role of p62 in p53 activation in AGS and HUH7 cells, we performed
knockdown of p62 in AGS and HUH7 cells (Fig. 6B). Knockdown of p62 abolished p53
activation in AGS cells and signiﬁcantly decreased p53 activation in HUH7 cells follow-
ing treatment with KPT-8602 (Fig. 6C). These results indicate an essential role of p62
accumulation in XPO1 inhibition-induced p53 activation in PML-NBs in AGS and HUH7
cells.
DISCUSSION
Numerous genetic engineering techniques using endonucleases to induce double-
stranded breaks (DSBs) at speciﬁc sites in the target DNA have been developed in the
last few decades. Endonucleases, such as transcription activator-like effector nucleases
(TALENs) or zinc ﬁnger nucleases (ZFNs), were previously used to inactivate targeted
genes, but some studies highlighted their lack of speciﬁcity and poor efﬁciency (27).
More recently, CRISPR-Cas9 has been shown to be an efﬁcient and precise tool for
genetic disruption or correction in vitro and in vivo (10, 11).
In this report, by performing a genome-wide CRISPR-Cas9 screening, we character-
ized gene essentiality in KSHV-transformed cells (13). KSHV, as a human oncogenic virus
in the family of Herpesviridae, is associated with several human malignancies, including
KS, primary effusion lymphoma (PEL), KSHV inﬂammatory cytokine syndrome (KICS),
and a subset of multicentric Castleman’s disease (MCD) (28). Using a model of KSHV-
induced cellular transformation of primary cells (13), we have identiﬁed essential genes
in both MM cells and KMM cells and observed an increase in survival ability in
KSHV-transformed cells compared to primary cells in a genome-wide CRISPR-Cas9
knockout screening (Fig. 1), conﬁrming the oncogenic nature of the virus. Moreover, we
have identiﬁed genes involved in the survival of KMM or MM cells (Fig. 2). In parallel,
we have observed a signiﬁcant positive correlation in gene essentiality between KMM
cells and other cancer cells observed by similar CRISPR-Cas9 screening (17), illustrating
the convergence of common survival features in these cancer cells.
Current therapies targeting latent infections of oncogenic viruses are often limited
in efﬁcacy and cannot eradicate the viruses. Numerous studies have performed CRISPR-
Cas9 screening in viral cancer models to identify novel therapeutic targets (29).
CRISPR-Cas9 genome editing in models of oncogenic viruses should facilitate the
identiﬁcation of vulnerable genes/mutations, viral and cellular oncoproteins, and es-
sential or restriction factors for infections. In particular, in the case of KSHV, CRISPR-
Cas9-mediated gene knockout enabled the identiﬁcation of RSK, an important sub-
strate of viral lytic protein ORF45 required for KSHV gene expression and production of
virions (30, 31). Recently, a CRISPR-Cas9 screening was performed in 8 PEL cell lines (32).
The results identiﬁed 210 essential genes across these cell lines and highlighted the
dependence on IRF4 and MDM2 pathways in PEL survival. They also showed the
dependency of PEL cells on cyclin D2 and c-Flip. In our study, we used matched primary
MM cells as controls and identiﬁed 1,259 genes (group 8) that are essential for
maintaining the proliferation of KMM cells, including 18 genes that had CRISPR score
ratios of 5 (32-fold) at day 21 over day 1 for KMM cells (Fig. 2). Among the top
enriched pathways are those that are related to the mTOR pathway, which has been
FIG 5 Legend (Continued)
KMM cells after treatment with 1 M KPT-8602 for 24 h analyzed by immunoﬂuorescence assay. The
sections were counterstained with DAPI, and pictures were taken with a confocal microscopy (magniﬁ-
cation, 600).
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FIG 6 XPO1 inhibition-induced p53 activation in PML-NBs depends on p62 nuclear accumulation in AGS
and HUH7 cells. (A) Expression of PML and p62 in AGS, HUH7, MM, and KMM cells after treatment with
(Continued on next page)
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shown to be the most effective target in KS patients in clinical studies (18), thus
validating the relevance of the model. These enriched pathways are likely vulnerable
targets of KSHV-induced malignancies. In agreement with the PEL screening results, we
identiﬁed IRF signaling as 1 of the 10 most highly enriched pathways, with genes losing
sgRNAs in KMM cells over MM cells; however, the hypoxia signaling pathway and p38
MAPK pathway are the top enriched pathways with genes losing sgRNAs. These
pathways have putative suppressive effects and hence are likely essential for maintain-
ing the homeostasis of KSHV-transformed cells.
The current study identiﬁed XPO1 as a critical factor for the proliferation of KSHV-
transformed cells. We conﬁrmed the essential role of XPO1 in cell proliferation and
cellular transformation of cell lines derived from gastric and liver cancers (Fig. 3). XPO1
dysregulation affects fundamental cellular processes such as inﬂammatory responses,
cell cycle, and apoptosis and might contribute to tumorigenesis (2). Since numerous
tumor suppressor proteins and oncoproteins, including p53, APC, Rb, NFAT, FOXO, p27,
nucleophosmin, BCR-ABL, eIF4E, surviving, and -catenin, harbor NES and are exported
from the nucleus to the cytoplasm by XPO1 to fulﬁll their growth-promoting and
antiapoptotic functions, nuclear-cytoplasmic transport, particularly transport mediated
by XPO1, is likely an effective general target for cancer (2).
Upregulation of XPO1 is observed in many types of cancer tissues such as lung
cancer, osteosarcoma, pancreatic cancer, ovarian cancer, cervical carcinoma, gastric and
hepatocellular carcinoma, myeloid and lymphoid leukemia, mantle cell lymphoma, and
multiple myeloma tissues (22). In parallel, XPO1 upregulation has been shown to affect
the functions of several oncogenes such as vascular endothelial growth factor receptor
(VEGF), epidermal growth factor (EGF) receptor, Cox-2, c-Myc, and HIF-1, which are not
the direct cargos of XPO1 (33). In addition to XPO1 upregulation, posttranslational
modiﬁcations of oncogenes and tumor suppressors can also alter or enhance their
nuclear-cytoplasmic transport by XPO1. For example, p53 sumoylation and ubiquitina-
tion have been shown to enhance its XPO1-mediated export (34, 35). Drug resistance
and poor prognosis have also been correlated with XPO1 upregulation in several
malignancies (36, 37). For example, XPO1 upregulation induces aberrant nuclear-
cytoplasmic export of topoisomerase II (Topo II) involved in DNA replication, tran-
scription, and chromatin segregation. Topo II is a target of numerous anticancer drugs
(38). However, its cytoplasmic export often induces resistance to Topo II-speciﬁc
inhibitors such as doxorubicin and etoposide. As a result, XPO1 inhibition increases
sensitivity to Topo II inhibitor (38). Hence, dual treatment with both Topo II inhibitor
and XPO1 inhibitor is likely to improve the efﬁcacy of cancer therapy.
The mechanism of XPO1 upregulation in cancer cells is still not well understood.
Chromosomal translocations as well as mutations or gains of copies of the XPO1 gene
could explain XPO1 overexpression. Indeed, a recurrent mutation in codon 571 of XPO1
gene has been reported in acute lymphoblastic leukemia (ALL) and in an adult with
acute myeloid leukemia (AML) with CBL syndrome displaying XPO1 overexpression (39,
40). Moreover, Myc and p53, often found modulated in cancer cells, have been shown
to positively and negatively alter the expression of XPO1, respectively (41). Finally, a
copy number gain in the XPO1 locus was also observed in patients affected by primary
mediastinal B-cell lymphoma (PMBL) and diffuse large B-cell lymphoma (DLBCL) (42,
43). We observed that there was an increase in XPO1 expression in KMM cells compared
to MM cells and that both vCyclin and pre-miR-K3 mediated XPO1 upregulation (Fig. 3A
to C). It would be interesting to investigate the effect of cell cycle progression on XPO1
upregulation.
FIG 6 Legend (Continued)
1 M KPT-8602 for 24 h analyzed by immunoﬂuorescence assay. The sections were counterstained with
DAPI, and pictures were taken with a confocal microscopy (magniﬁcation, 600). (B) Expression of p62
in AGS and HUH7 cells following siRNA knockdown analyzed by Western blotting. (C) Analysis of p-p53
in AGS and HUH7 cells after treatment with 1 M KPT-8602 for 24 h following siRNA knockdown of p62
by Western blotting.
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SINE compounds have been used to treat several types of cancer; among them,
KPT-330 is currently in phase 1 and 2 clinical trials in numerous solid and hematologic
malignancies with and without its use in combination with other chemotherapeutic
agents and has shown promising results (33). To decrease adverse side effects, a second
generation of SINE compounds that include KPT-8602 and that show improved toler-
ability has been developed and tested in clinical trials (44). In this report, we have
shown that KPT-8602 inhibits the cell proliferation and cellular transformation of KMM,
AGS, and HUH7 cells (Fig. 3), conﬁrming the anticancer effect of members of the SINE
family. Indeed, KPT-8602 has been shown to inhibit the proliferation of leukemia cells
derived from ALL in vitro and to increase the animal survival rate in ALL xenograft
models (45).
SINE compounds can block XPO1-mediated export and can therefore cause mislo-
calization of tumor suppressors or oncoproteins and decrease the rate of survival of
cancer cells (1). A previous study highlighted the nuclear accumulation of p21, p27, and
FOXO proteins after treatment with SINE compound S109 in colorectal cancer cells (46).
Recently, KPT-330 has been shown to induce p53 and p21 retention within the nucleus
in gastric cancer cells (47). In our study, we observed cell cycle arrest associated with
p53 activation in KMM, AGS, and HUH7 cells after KPT-8602 treatment. However, we
found that different types of cancer cells respond differently to this inhibitor, with KMM
cells manifesting G2/M arrest and AGS and HUH7 cells manifesting G0/G1 arrest
(Fig. 4A). Consistent with these results, the mechanism mediating p53 activation in AGS
and HUH7 cells is different from that in KMM cells. We have observed p53 nuclear
accumulation in AGS and HUH7 cells but not in KMM cells after KPT-8602 treatment
(Fig. 5B).
PML-NBs recruit a variety of proteins and modulate their posttranslational modiﬁ-
cations. In particular, p53 and its regulators (ARF, HIPK2, CBP, MDM2, SIRT1, and MOZ)
trafﬁc through PML-NBs, suggesting that these nuclear bodies could regulate p53
activation by posttranslational modiﬁcations (48). Indeed, disruption of PML-NBs inhib-
its p53 activation and induces expression of its downstream genes, such as Bax and p21
(9, 49, 50); however, the underlying mechanism remains unclear. Interestingly, we have
conﬁrmed that p53 nuclear accumulation depends on the formation of PML-NBs after
XPO1 inhibition in AGS and HUH7 cells (Fig. 4C to E). On the other hand, p53 activation
in KMM after XPO1 inhibition does not depend on the formation of PML-NBs, which
remains to be further explored.
Other NBs have been identiﬁed in the nucleus, and some studies suggested possible
fusion events among them, forming hybrid NBs (51). Interestingly, XPO1 is involved in
the formation of CRM1-nucleolar bodies (CNoBs), and its inhibition by XPO1 inhibitor
leptomycin B disrupts CNoBs (52). Another type of NB involved with p62 (SQSTM1) was
identiﬁed by imaging (26). p62 protein is mostly described as a scaffold cytoplasmic
protein involved in autophagy processes by interacting with LC3, thereby mediating
the recruitment of LC3 to polyubiquitinated protein aggregates to form autophago-
some in the cytoplasm (53). Unlike its cytoplasmic function, the role of p62 within the
nucleus is still not well understood. While PML-NBs are ubiquitous, CNoBs and p62-NBs
are stress induced. It has been reported that p62-NBs are colocalized with PML-NBs
upon inhibition of CNoBs (51), highlighting the role of nuclear p62 in the recruitment
of polyubiquitinated proteins to PML-NBs (26).
The role of p62 in cancer development is still controversial (54). The expression level
of p62 can be increased in cancer cells, and its overexpression has been shown to
enhance cellular transformation through the activation of NRF2, mTORC1, and c-Myc
pathways in liver cancer cells, independently of the autophagy pathway (55). On the
other hand, in a nontumorigenic environment, p62 attenuates inﬂammation and
ﬁbrosis (56) and p62 loss has been shown to increase tumorigenesis in epithelial cells
(57).
In this study, we demonstrated the essential role of p62 in the activation of the p53
tumor suppressor after XPO1 inhibition in AGS and HUH7 cells (Fig. 5 and 6). We
observed nuclear accumulation of p62, which is colocalized with p53 after XPO1
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inhibition in AGS and HUH7 cells. In parallel, we observed colocalization of p62 with
PML-NBs, hence supporting the hypothesis of formation of PML-p62 hybrid NBs under
stress conditions (26). Finally, we demonstrated for the ﬁrst time that nuclear accumu-
lation of p62 is required for p53 phosphorylation and activation within the PML-NBs
after KPT-8602 treatment in AGS and HUH7 cells, demonstrating the indirect role of p62
in regulating the function of p53 in these cancer cells. Interestingly, while XPO1
inhibition causes an increase in the level of p62 in KMM cells, it neither leads to p62
nuclear accumulation nor mediates p53 activation (Fig. 5 and 6). It would be interesting
to investigate whether the increase in the level of p62 after XPO1 inhibition contributes
to the G2/M cell cycle arrest in KMM cells.
MATERIALS AND METHODS
Cells and inhibitor. Rat primary embryonic mesenchymal stem cells (MM cells), KSHV-transformed
MM cells (KMM cells), and AGS and HUH7 cell lines were maintained in Dulbecco modiﬁed Eagle medium
(DMEM) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich), 4 mM L-glutamine, and
10 g/ml penicillin and streptomycin. KPT-8602 was obtained from Selleckchem.
Rat sgRNA library cloning. Rat sgRNA library cloning was carried out as previously described (58).
This sgRNA library consists of a library of 59,520 unique sgRNAs targeting 19,840 coding genes, each with
3 independent sgRNAs, and 10 nontargeting sgRNAs, for a total of 59,530 sgRNAs. Speciﬁcally, we
carefully chose three target sites for each gene to cover the most common exons in transcript variants
ranging from 3% to 70% in the coding sequence (CDS) region from the rat genome (Rattus norvegicus;
Rnor 5.0 version). Furthermore, we chose the target sites by avoiding potential off-target effects and
in-frame mutations using Cas-OFFinder (59) and Cas-Designer (60) (http://www.rgenome.net/).
Lentiviral production of the sgRNA library. Lentiviral production was carried out as previously
described (61, 62). Brieﬂy, HEK293T cells were seeded at 40% conﬂuence 1 day before transfection in
DMEM supplemented with 10% serum. One-hour prior to transfection, DMEM was removed and fresh
Opti-MEM medium (Life Technologies) was added. Lipofectamine 2000 (Life Technologies) was used to
transfect 20 g of lentiCRISPR plasmid library, 10 g of pVSVg, and 15 g of psPAX2. Lipofectamine 2000
(100 l) was diluted in 4 ml of Opti-MEM, and after 5 min, it was added to the mixture of plasmid DNAs,
incubated for 20 min, and then added to the cells. The medium was refreshed after 6 h and collected
after 3 days. The supernatant was centrifuged at 3,000 rpm at 4°C for 10 min to pellet cell debris, ﬁltered
(0.45-m pore size), and concentrated by ultracentrifugation (Beckmann) at 24,000 rpm for 2 h at 4°C.
The virus preparation was ﬁnally resuspended overnight at 4°C in DMEM, divided into aliquots, and
stored at 80°C.
Lentiviral transduction of the sgRNA library. Lentiviral transduction was carried out as previously
described (61). Cells were transduced with the short hairpin RNA (shRNA) library via “spinfection” at a
multiplicity of infection (MOI) of 0.3 in full DMEM supplemented with 10% fetal bovine serum, 4 mM
L-glutamine, and 10 g/ml penicillin and streptomycin in the presence of 10 g/ml of Polybrene. Flasks
containing cells were centrifuged at 2,000 rpm for 2 h at 37°C. After the spin step, the medium was
removed and fresh DMEM was added to the cells.
Genome DNA sequencing. Genome DNA sequencing was carried out as previously described (10).
Genomic DNA was extracted using a QiAMP kit (Qiagen), and PCR was performed in two steps. First, the
input genomic DNA was ampliﬁed in order to achieve 300 coverage over the sgRNA library using
primers F1 (TCG TCG GCA GCG TCA GAT GTG TAT AAG AGA CAG TAT CTT GTG GAA AGG ACG AAA) and
R1 (GTC TCG TGG GCT CGG AGA TGT GTA TAA GAG ACA GTT ATT TTA ACT TGC TAT TTC TAG CTC). Then,
to attach Illumina adaptors and barcode samples, a second PCR was carried out using primers F2 (AAT
GAT ACG GCG ACC ACC GAG ATC TAC ACT CTT TCC CTA CAC GAC GCT CTT CCG ATC T) and R2 (CAA GCA
GAA GAC GGC ATA CGA GAT GTG ACT GGA GTT CAG ACG TGT GCT CTT CCG ATC T). Amplicons from the
second PCR were subjected to gel extraction, quantiﬁed, mixed, and sequenced using a HiSeq 2500
instrument (Illumina).
Ingenuity pathway analysis. The pathways that were differentially enriched at day 21 over day 1
postransduction in KMM cells over MM cells were evaluated using IPA software (Ingenuity H Systems,
USA).
Soft agar assay. Soft agar assay was carried out as previously described (15).
Cell proliferation assay.MM, KMM, AGS, and HUH7 cells plated at a density of 200,000 cells/well and
treated with dimethyl sulfoxide (DMSO) or KPT-8602 at different concentrations were counted daily using
a Malassez chamber.
Western blotting. Western blotting was carried out as previously described (62). Primary antibodies
to -actin (Santa Cruz), p62 (CST), SIRT1 (CST), Cas9-hemagglutinin (Cas9-HA; Santa Cruz), PML (CST),
XPO1 (CST), p53 (CST), and phospho-p53 (CST) were used.
Immunoﬂuorescence assay. Cells were ﬁxed in methanol for 10 min at room temperature and
processed for antibody staining as previously described (63). Immunostaining was performed using
anti-p62 antibody (CST), anti-PML antibody (CST), or anti-phospho-p53 antibody (CST). Alexa488- and
Alexa568-conjugated secondary antibodies (Thermo Fisher Scientiﬁc) were used to reveal the signals.
Nuclei were counterstained with DAPI (4=,6-diamidino-2-phenylindole). Tissue sections that had not
been subjected to incubation with primary antibodies were used as negative controls. Images of
representative areas were acquired using a confocal ﬂuorescence microscopy with a 60 objective
(Nikon Eclipse C1).
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Cell cycle assay. The cell cycle was analyzed as previously described (62). MM, KMM, AGS, and HUH7
cells pulsed with 10 M 5-bromo-2=-deoxyuridine (BrdU) (B5002; Sigma-Aldrich) were stained with
propidium iodide (P4864; Sigma-Aldrich). BrdU was detected by ﬂow cytometry with a Paciﬁc Blue-
conjugated anti-BrdU antibody (B35129; Thermo Fisher Scientiﬁc). Results were analyzed using FlowJo
software (FlowJo LLC, USA).
Statistical analysis. Statistical analysis was performed using the Kolmogorov-Smirnov test or the
two-tailed t test as indicated in the ﬁgure legends, and a P value of 0.05 was considered signiﬁcant.
Single, double, and triple asterisks in the ﬁgures represent P values of 0.05, 0.01, and 0.001,
respectively, while NS indicates that the results were not statistically signiﬁcant.
Data availability. All CRISPR data generated in this study have been submitted to the NCBI Gene
Expression Omnibus and will become publicly available with accession number GSE125507.
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